1. Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC);Latif;Invest New Drugs,2005
2. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormonerefractory prostate cancer;Sternberg;Oncology,2005
3. Petrylak DP, Sartor O, Witjes F, et al. A phase III, randomized, double-blind trial of satraplatin and prednisone vs placebo and prednisone for patients with hormone refractory prostate cancer (HRPC). Presented at: the 2007 Prostate Cancer Symposium; February 22-24, 2007; Orlando, FL. Abstract #145.
4. Berthold DR, Pond G, De Wit R, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival of the TAX 327 study. Presented at: the 2007 Prostate Cancer Symposium; February 22-24, 2007; Orlando, FL. Abstract #147.
5. Capecitabine in hormone-resistant metastatic prostatic carcinoma -a phase II trial;Morant;Br J Cancer,2004